Clough Capital
Clough Capital Clough is a Boston-based investment advisory firm which manages approximately $3.9 billion in assets: $1.7 billion in hedge fund and institutional accounts; $92 million in open-end mutual funds; and $2.1 billion in three closed-end funds (as of February 28, 2011) - Clough Global Allocation (GLV), Clough Global Equity (GLQ), and the Clough Global Opportunities Fund (GLO). The firm uses a global and theme-based approach and invests in securities on a global basis. Clough was founded in 2000 by Chuck Clough and partners James Canty and Eric Brock. These three are the portfolio managers for the Clough Global Allocation Fund.
View Older Stories View More Recent Stories
-
Clough Global Closed End Funds Boards of Trustees Reauthorize Share Repurchase Programs
-
Clough Global Dividend and Income Fund
-
Clough Global Opportunities Fund
-
Clough Global Equity Fund
-
Form 13F-HR CLOUGH CAPITAL PARTNERS For: Sep 30
-
Clough Global Dividend and Income Fund Declares a Monthly Cash Distribution of $0.1032 Per Share
-
Clough Global Opportunities Fund Declares a Monthly Cash Distribution of $0.0860 Per Share
-
Clough Global Equity Fund Declares a Monthly Cash Distribution of $0.0989 Per Share
-
Clough Global Dividend and Income Fund
-
Clough Global Opportunities Fund
-
Clough Global Equity Fund
-
Form 13F-HR CLOUGH CAPITAL PARTNERS For: Jun 30
-
Clough Global Equity Fund Announces Fund Distribution Rate Change and Declares Monthly Cash Distribution
-
Clough Global Opportunities Fund Announces Fund Distribution Rate Change and Declares Monthly Cash Distribution
-
Clough Global Dividend and Income Fund Announces Fund Distribution Rate Change and Declares Monthly Cash Distribution
-
Clough Global Equity Fund
-
Clough Global Opportunities Fund
-
Clough Global Allocation Fund
-
Clough Global Allocation Fund Changes Name to Clough Global Dividend and Income Fund
-
Clough Global Equity Fund
-
Clough Global Allocation Fund
-
Clough Global Opportunities Fund
-
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
-
Form 13F-HR CLOUGH CAPITAL PARTNERS For: Mar 31
-
Clough Global Opportunities Fund Declares a Monthly Cash Distribution of $0.100 Per Share
-
Clough Global Equity Fund Declares a Monthly Cash Distribution of $0.115 Per Share
-
Clough Global Allocation Fund Declares a Monthly Cash Distribution of $0.120 Per Share
-
Clough Global Opportunities Fund
-
Clough Global Equity Fund
-
Clough Global Allocation Fund
-
Clough Global Opportunities Fund
-
Clough Global Equity Fund
-
Clough Global Allocation Fund
-
Form SC 13G/A Cardiome Pharma Corp Filed by: CLOUGH CAPITAL PARTNERS L P
-
Clough Global Closed End Funds Boards of Trustees Reauthorize Share Repurchase Programs
-
Clough Global Opportunities Fund
-
Clough Global Allocation Fund
-
Clough Global Equity Fund
-
Form 13F-HR CLOUGH CAPITAL PARTNERS For: Dec 31
-
ARMO BioSciences Raises $50 Million Series C Financing
-
Clough Global Allocation Fund Declares a Monthly Cash Distribution of $0.120 Per Share
-
Clough Global Equity Fund Declares a Monthly Cash Distribution of $0.115 Per Share
-
Clough Global Opportunities Fund Declares a Monthly Cash Distribution of $0.100 Per Share
-
Clough Global Allocation Fund
-
Clough Global Opportunities Fund
-
Clough Global Equity Fund
-
Form SC 13G/A VERACYTE, INC. Filed by: CLOUGH CAPITAL PARTNERS L P
-
Form SC 13G HEALTHWAYS, INC Filed by: CLOUGH CAPITAL PARTNERS L P
-
Form SC 13G Kura Oncology, Inc. Filed by: CLOUGH CAPITAL PARTNERS L P
-
O’Neil Firms Begin Next Half-Century of Service with an Infusion of New Leadership
